#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=5. Conclusions and Perspectives
1-1	0-2	5.	_	_	_	_
1-2	3-14	Conclusions	abstract	new	_	_
1-3	15-18	and	_	_	_	_
1-4	19-31	Perspectives	abstract	new	_	_

#Text=EGFR-TKIs are currently the standard first-line treatment of patients with advanced NSCLC with activating EGFR mutations .
2-1	32-41	EGFR-TKIs	abstract	new	coref	2-3[4_0]
2-2	42-45	are	_	_	_	_
2-3	46-55	currently	abstract[4]	giv[4]	coref	6-2[0_4]
2-4	56-59	the	abstract[4]	giv[4]	_	_
2-5	60-68	standard	abstract[4]	giv[4]	_	_
2-6	69-79	first-line	abstract[4]	giv[4]	_	_
2-7	80-89	treatment	abstract[4]	giv[4]	_	_
2-8	90-92	of	abstract[4]	giv[4]	_	_
2-9	93-101	patients	abstract[4]|person[5]	giv[4]|new[5]	coref	13-24[102_5]
2-10	102-106	with	abstract[4]|person[5]	giv[4]|new[5]	_	_
2-11	107-115	advanced	abstract[4]|person[5]|abstract[6]	giv[4]|new[5]|new[6]	coref	8-9[50_6]
2-12	116-121	NSCLC	abstract[4]|person[5]|abstract[6]	giv[4]|new[5]|new[6]	_	_
2-13	122-126	with	_	_	_	_
2-14	127-137	activating	_	_	_	_
2-15	138-142	EGFR	abstract|abstract[8]	new|new[8]	_	_
2-16	143-152	mutations	abstract[8]	new[8]	_	_
2-17	153-154	.	_	_	_	_

#Text=These targeted therapies are usually well tolerated comparative to conventional chemotherapy .
3-1	155-160	These	abstract[9]	new[9]	_	_
3-2	161-169	targeted	abstract[9]	new[9]	_	_
3-3	170-179	therapies	abstract[9]	new[9]	_	_
3-4	180-183	are	_	_	_	_
3-5	184-191	usually	_	_	_	_
3-6	192-196	well	_	_	_	_
3-7	197-206	tolerated	_	_	_	_
3-8	207-218	comparative	_	_	_	_
3-9	219-221	to	_	_	_	_
3-10	222-234	conventional	object[10]	new[10]	coref	20-8[146_10]
3-11	235-247	chemotherapy	object[10]	new[10]	_	_
3-12	248-249	.	_	_	_	_

#Text=The self-oral administration of the drug positively contributes to improving patient compliance and reducing the use of hospital resources .
4-1	250-253	The	organization[11]	new[11]	coref	5-7[0_11]
4-2	254-263	self-oral	organization[11]	new[11]	_	_
4-3	264-278	administration	organization[11]	new[11]	_	_
4-4	279-281	of	organization[11]	new[11]	_	_
4-5	282-285	the	organization[11]|substance[12]	new[11]|new[12]	coref	5-18[0_12]
4-6	286-290	drug	organization[11]|substance[12]	new[11]|new[12]	_	_
4-7	291-301	positively	_	_	_	_
4-8	302-313	contributes	_	_	_	_
4-9	314-316	to	_	_	_	_
4-10	317-326	improving	_	_	_	_
4-11	327-334	patient	person|abstract[14]	new|new[14]	coref|coref	5-24|5-24
4-12	335-345	compliance	abstract[14]	new[14]	_	_
4-13	346-349	and	_	_	_	_
4-14	350-358	reducing	_	_	_	_
4-15	359-362	the	abstract[15]	new[15]	coref	18-38[138_15]
4-16	363-366	use	abstract[15]	new[15]	_	_
4-17	367-369	of	abstract[15]	new[15]	_	_
4-18	370-378	hospital	abstract[15]|place|abstract[17]	new[15]|new|new[17]	_	_
4-19	379-388	resources	abstract[15]|abstract[17]	new[15]|new[17]	_	_
4-20	389-390	.	_	_	_	_

#Text=However , this non-invasive route of administration is also associated with unpredictable bioavailability , increased risk of drug interactions , and concerns about patient safety , surveillance , and follow-up .
5-1	391-398	However	_	_	_	_
5-2	399-400	,	_	_	_	_
5-3	401-405	this	abstract[18]	new[18]	_	_
5-4	406-418	non-invasive	abstract[18]	new[18]	_	_
5-5	419-424	route	abstract[18]	new[18]	_	_
5-6	425-427	of	abstract[18]	new[18]	_	_
5-7	428-442	administration	abstract[18]|organization	new[18]|giv	_	_
5-8	443-445	is	_	_	_	_
5-9	446-450	also	_	_	_	_
5-10	451-461	associated	_	_	_	_
5-11	462-466	with	_	_	_	_
5-12	467-480	unpredictable	abstract[20]	new[20]	_	_
5-13	481-496	bioavailability	abstract[20]	new[20]	_	_
5-14	497-498	,	_	_	_	_
5-15	499-508	increased	event[21]	new[21]	_	_
5-16	509-513	risk	event[21]	new[21]	_	_
5-17	514-516	of	event[21]	new[21]	_	_
5-18	517-521	drug	event[21]|substance|abstract[23]	new[21]|giv|new[23]	coref|coref	18-22|18-22
5-19	522-534	interactions	event[21]|abstract[23]	new[21]|new[23]	_	_
5-20	535-536	,	_	_	_	_
5-21	537-540	and	_	_	_	_
5-22	541-549	concerns	abstract[24]	new[24]	_	_
5-23	550-555	about	abstract[24]	new[24]	_	_
5-24	556-563	patient	abstract[24]|person|abstract[26]	new[24]|giv|new[26]	coref|coref	7-15|7-15
5-25	564-570	safety	abstract[24]|abstract[26]	new[24]|new[26]	_	_
5-26	571-572	,	abstract[24]	new[24]	_	_
5-27	573-585	surveillance	abstract[24]|abstract	new[24]|new	_	_
5-28	586-587	,	abstract[24]	new[24]	_	_
5-29	588-591	and	abstract[24]	new[24]	_	_
5-30	592-601	follow-up	abstract[24]|event	new[24]|new	coref	9-28[64_0]
5-31	602-603	.	_	_	_	_

#Text=Chronic EGFR-TKIs underdosage may favor the selection of resistant clones and thus disease progression , and overdosage may increase the risk of dose-related side effects .
6-1	604-611	Chronic	abstract[30]	new[30]	_	_
6-2	612-621	EGFR-TKIs	abstract|abstract[30]	giv|new[30]	coref	8-4
6-3	622-633	underdosage	abstract[30]	new[30]	_	_
6-4	634-637	may	_	_	_	_
6-5	638-643	favor	_	_	_	_
6-6	644-647	the	abstract[31]	new[31]	_	_
6-7	648-657	selection	abstract[31]	new[31]	_	_
6-8	658-660	of	abstract[31]	new[31]	_	_
6-9	661-670	resistant	abstract[31]|abstract[32]	new[31]|new[32]	_	_
6-10	671-677	clones	abstract[31]|abstract[32]	new[31]|new[32]	_	_
6-11	678-681	and	abstract[31]	new[31]	_	_
6-12	682-686	thus	abstract[31]|abstract[34]	new[31]|new[34]	_	_
6-13	687-694	disease	abstract[31]|abstract|abstract[34]	new[31]|new|new[34]	coref	8-20[53_0]
6-14	695-706	progression	abstract[31]|abstract[34]	new[31]|new[34]	_	_
6-15	707-708	,	_	_	_	_
6-16	709-712	and	_	_	_	_
6-17	713-723	overdosage	abstract	new	_	_
6-18	724-727	may	_	_	_	_
6-19	728-736	increase	_	_	_	_
6-20	737-740	the	abstract[36]	new[36]	_	_
6-21	741-745	risk	abstract[36]	new[36]	_	_
6-22	746-748	of	abstract[36]	new[36]	_	_
6-23	749-761	dose-related	abstract[36]|abstract[37]	new[36]|new[37]	coref	7-8[40_37]
6-24	762-766	side	abstract[36]|abstract[37]	new[36]|new[37]	_	_
6-25	767-774	effects	abstract[36]|abstract[37]	new[36]|new[37]	_	_
6-26	775-776	.	_	_	_	_

#Text=Self-administration also means that the severity of side effects can be considerably impacted by patient behavior ( e. g. , dietary habits , self-medicating , smoker status ) .
7-1	777-796	Self-administration	abstract	new	_	_
7-2	797-801	also	_	_	_	_
7-3	802-807	means	_	_	_	_
7-4	808-812	that	_	_	_	_
7-5	813-816	the	abstract[39]	new[39]	_	_
7-6	817-825	severity	abstract[39]	new[39]	_	_
7-7	826-828	of	abstract[39]	new[39]	_	_
7-8	829-833	side	abstract[39]|abstract[40]	new[39]|giv[40]	coref	24-32[197_40]
7-9	834-841	effects	abstract[39]|abstract[40]	new[39]|giv[40]	_	_
7-10	842-845	can	_	_	_	_
7-11	846-848	be	_	_	_	_
7-12	849-861	considerably	_	_	_	_
7-13	862-870	impacted	_	_	_	_
7-14	871-873	by	_	_	_	_
7-15	874-881	patient	person|abstract[42]	giv|new[42]	appos|coref|appos|coref	7-21[44_42]|11-14|7-21[44_42]|11-14
7-16	882-890	behavior	abstract[42]	new[42]	_	_
7-17	891-892	(	_	_	_	_
7-18	893-895	e.	_	_	_	_
7-19	896-898	g.	_	_	_	_
7-20	899-900	,	_	_	_	_
7-21	901-908	dietary	abstract|abstract[44]	new|giv[44]	appos|appos	7-24[0_44]|7-24[0_44]
7-22	909-915	habits	abstract[44]	giv[44]	_	_
7-23	916-917	,	_	_	_	_
7-24	918-933	self-medicating	abstract	giv	appos	7-26[47_0]
7-25	934-935	,	_	_	_	_
7-26	936-942	smoker	person|abstract[47]	new|giv[47]	_	_
7-27	943-949	status	abstract[47]	giv[47]	_	_
7-28	950-951	)	_	_	_	_
7-29	952-953	.	_	_	_	_

#Text=To date , EGFR-TKIs can be administered in advanced NSCLC for a long period of time , usually until the disease progresses or unacceptable toxicity occurs .
8-1	954-956	To	_	_	_	_
8-2	957-961	date	time	new	_	_
8-3	962-963	,	_	_	_	_
8-4	964-973	EGFR-TKIs	abstract	giv	_	_
8-5	974-977	can	_	_	_	_
8-6	978-980	be	_	_	_	_
8-7	981-993	administered	_	_	_	_
8-8	994-996	in	_	_	_	_
8-9	997-1005	advanced	abstract[50]	giv[50]	coref	27-24[0_50]
8-10	1006-1011	NSCLC	abstract[50]	giv[50]	_	_
8-11	1012-1015	for	_	_	_	_
8-12	1016-1017	a	time[51]	new[51]	_	_
8-13	1018-1022	long	time[51]	new[51]	_	_
8-14	1023-1029	period	time[51]	new[51]	_	_
8-15	1030-1032	of	time[51]	new[51]	_	_
8-16	1033-1037	time	time[51]|time	new[51]|new	_	_
8-17	1038-1039	,	_	_	_	_
8-18	1040-1047	usually	_	_	_	_
8-19	1048-1053	until	_	_	_	_
8-20	1054-1057	the	abstract[53]	giv[53]	coref	13-4[0_53]
8-21	1058-1065	disease	abstract[53]	giv[53]	_	_
8-22	1066-1076	progresses	_	_	_	_
8-23	1077-1079	or	_	_	_	_
8-24	1080-1092	unacceptable	abstract[54]	new[54]	coref	9-29[0_54]
8-25	1093-1101	toxicity	abstract[54]	new[54]	_	_
8-26	1102-1108	occurs	_	_	_	_
8-27	1109-1110	.	_	_	_	_

#Text=As early intervention with supportive care strategies can minimize the intensity of adverse reactions or allow for appropriate dose adjustments without the need to discontinue treatment , acute toxicity follow-up and side effect management is of major interest .
9-1	1111-1113	As	_	_	_	_
9-2	1114-1119	early	_	_	_	_
9-3	1120-1132	intervention	_	_	_	_
9-4	1133-1137	with	_	_	_	_
9-5	1138-1148	supportive	abstract[56]	new[56]	coref	11-4[78_56]
9-6	1149-1153	care	abstract|abstract[56]	new|new[56]	coref	11-27[86_0]
9-7	1154-1164	strategies	abstract[56]	new[56]	_	_
9-8	1165-1168	can	_	_	_	_
9-9	1169-1177	minimize	_	_	_	_
9-10	1178-1181	the	abstract[57]	new[57]	_	_
9-11	1182-1191	intensity	abstract[57]	new[57]	_	_
9-12	1192-1194	of	abstract[57]	new[57]	_	_
9-13	1195-1202	adverse	abstract[57]|abstract[58]	new[57]|new[58]	_	_
9-14	1203-1212	reactions	abstract[57]|abstract[58]	new[57]|new[58]	_	_
9-15	1213-1215	or	_	_	_	_
9-16	1216-1221	allow	_	_	_	_
9-17	1222-1225	for	_	_	_	_
9-18	1226-1237	appropriate	event[60]	new[60]	_	_
9-19	1238-1242	dose	quantity|event[60]	new|new[60]	coref	21-20
9-20	1243-1254	adjustments	event[60]	new[60]	_	_
9-21	1255-1262	without	_	_	_	_
9-22	1263-1266	the	abstract[61]	new[61]	coref	16-18[116_61]
9-23	1267-1271	need	abstract[61]	new[61]	_	_
9-24	1272-1274	to	_	_	_	_
9-25	1275-1286	discontinue	_	_	_	_
9-26	1287-1296	treatment	event	new	coref	10-38
9-27	1297-1298	,	_	_	_	_
9-28	1299-1304	acute	event[64]	giv[64]	coref	19-4[142_64]
9-29	1305-1313	toxicity	abstract|event[64]	giv|giv[64]	coref	14-8
9-30	1314-1323	follow-up	event[64]	giv[64]	_	_
9-31	1324-1327	and	_	_	_	_
9-32	1328-1332	side	abstract[66]	new[66]	_	_
9-33	1333-1339	effect	abstract|abstract[66]	new|new[66]	_	_
9-34	1340-1350	management	abstract[66]	new[66]	_	_
9-35	1351-1353	is	_	_	_	_
9-36	1354-1356	of	_	_	_	_
9-37	1357-1362	major	abstract[67]	new[67]	_	_
9-38	1363-1371	interest	abstract[67]	new[67]	_	_
9-39	1372-1373	.	_	_	_	_

#Text=Therefore , medical oncologists should not only understand the AEs associated with these drugs , but also develop the necessary skills to detect and treat them to reduce morbidity and mortality as well as premature discontinuation of treatment .
10-1	1374-1383	Therefore	_	_	_	_
10-2	1384-1385	,	_	_	_	_
10-3	1386-1393	medical	person[68]	new[68]	coref	18-3[125_68]
10-4	1394-1405	oncologists	person[68]	new[68]	_	_
10-5	1406-1412	should	_	_	_	_
10-6	1413-1416	not	_	_	_	_
10-7	1417-1421	only	_	_	_	_
10-8	1422-1432	understand	_	_	_	_
10-9	1433-1436	the	abstract[69]	new[69]	coref	16-16[0_69]
10-10	1437-1440	AEs	abstract[69]	new[69]	_	_
10-11	1441-1451	associated	_	_	_	_
10-12	1452-1456	with	_	_	_	_
10-13	1457-1462	these	substance[70]	new[70]	_	_
10-14	1463-1468	drugs	substance[70]	new[70]	_	_
10-15	1469-1470	,	_	_	_	_
10-16	1471-1474	but	_	_	_	_
10-17	1475-1479	also	_	_	_	_
10-18	1480-1487	develop	_	_	_	_
10-19	1488-1491	the	abstract[71]	new[71]	ana	10-26[0_71]
10-20	1492-1501	necessary	abstract[71]	new[71]	_	_
10-21	1502-1508	skills	abstract[71]	new[71]	_	_
10-22	1509-1511	to	_	_	_	_
10-23	1512-1518	detect	_	_	_	_
10-24	1519-1522	and	_	_	_	_
10-25	1523-1528	treat	_	_	_	_
10-26	1529-1533	them	abstract	giv	_	_
10-27	1534-1536	to	_	_	_	_
10-28	1537-1543	reduce	_	_	_	_
10-29	1544-1553	morbidity	abstract	new	_	_
10-30	1554-1557	and	_	_	_	_
10-31	1558-1567	mortality	event	new	_	_
10-32	1568-1570	as	_	_	_	_
10-33	1571-1575	well	_	_	_	_
10-34	1576-1578	as	_	_	_	_
10-35	1579-1588	premature	event[75]	new[75]	coref	23-27[0_75]
10-36	1589-1604	discontinuation	event[75]	new[75]	_	_
10-37	1605-1607	of	event[75]	new[75]	_	_
10-38	1608-1617	treatment	event[75]|event	new[75]|giv	coref	11-23
10-39	1618-1619	.	_	_	_	_

#Text=Patient education on these strategies is also of major importance and can improve patient tolerance , quality of life , and overall treatment outcome by initiating supportive care soon after symptoms occur .
11-1	1620-1627	Patient	abstract[77]	new[77]	coref	18-11[128_77]
11-2	1628-1637	education	abstract[77]	new[77]	_	_
11-3	1638-1640	on	abstract[77]	new[77]	_	_
11-4	1641-1646	these	abstract[77]|abstract[78]	new[77]|giv[78]	coref	17-19[124_78]
11-5	1647-1657	strategies	abstract[77]|abstract[78]	new[77]|giv[78]	_	_
11-6	1658-1660	is	_	_	_	_
11-7	1661-1665	also	_	_	_	_
11-8	1666-1668	of	_	_	_	_
11-9	1669-1674	major	abstract[79]	new[79]	coref	19-1[140_79]
11-10	1675-1685	importance	abstract[79]	new[79]	_	_
11-11	1686-1689	and	_	_	_	_
11-12	1690-1693	can	_	_	_	_
11-13	1694-1701	improve	_	_	_	_
11-14	1702-1709	patient	person|abstract[81]	giv|new[81]	coref|coref	18-11|18-11
11-15	1710-1719	tolerance	abstract[81]	new[81]	_	_
11-16	1720-1721	,	_	_	_	_
11-17	1722-1729	quality	abstract[82]	new[82]	_	_
11-18	1730-1732	of	abstract[82]	new[82]	_	_
11-19	1733-1737	life	abstract[82]|abstract	new[82]|new	coref	20-27
11-20	1738-1739	,	_	_	_	_
11-21	1740-1743	and	_	_	_	_
11-22	1744-1751	overall	abstract[85]	new[85]	_	_
11-23	1752-1761	treatment	event|abstract[85]	giv|new[85]	coref	13-17
11-24	1762-1769	outcome	abstract[85]	new[85]	_	_
11-25	1770-1772	by	_	_	_	_
11-26	1773-1783	initiating	_	_	_	_
11-27	1784-1794	supportive	abstract[86]	giv[86]	coref	27-18[225_86]
11-28	1795-1799	care	abstract[86]	giv[86]	_	_
11-29	1800-1804	soon	_	_	_	_
11-30	1805-1810	after	_	_	_	_
11-31	1811-1819	symptoms	abstract	new	_	_
11-32	1820-1825	occur	_	_	_	_
11-33	1826-1827	.	_	_	_	_

#Text=Within this guidance and preventive strategy , the pharmacist can play a major role .
12-1	1828-1834	Within	_	_	_	_
12-2	1835-1839	this	abstract[88]	new[88]	_	_
12-3	1840-1848	guidance	abstract[88]	new[88]	_	_
12-4	1849-1852	and	_	_	_	_
12-5	1853-1863	preventive	abstract[89]	new[89]	_	_
12-6	1864-1872	strategy	abstract[89]	new[89]	_	_
12-7	1873-1874	,	_	_	_	_
12-8	1875-1878	the	person[90]	new[90]	_	_
12-9	1879-1889	pharmacist	person[90]	new[90]	_	_
12-10	1890-1893	can	_	_	_	_
12-11	1894-1898	play	_	_	_	_
12-12	1899-1900	a	abstract[91]	new[91]	_	_
12-13	1901-1906	major	abstract[91]	new[91]	_	_
12-14	1907-1911	role	abstract[91]	new[91]	_	_
12-15	1912-1913	.	_	_	_	_

#Text=Good knowledge of disease monitoring , response milestones , and the risks versus benefits of the treatment options allows pharmacists to better advise patients or counsel patients more effectively .
13-1	1914-1918	Good	abstract[92]	new[92]	_	_
13-2	1919-1928	knowledge	abstract[92]	new[92]	_	_
13-3	1929-1931	of	abstract[92]	new[92]	_	_
13-4	1932-1939	disease	abstract[92]|abstract|event[94]	new[92]|giv|new[94]	coref|coref|coref|coref	18-23[0_94]|26-25|18-23[0_94]|26-25
13-5	1940-1950	monitoring	abstract[92]|event[94]	new[92]|new[94]	_	_
13-6	1951-1952	,	abstract[92]	new[92]	_	_
13-7	1953-1961	response	abstract[92]|abstract|event[96]	new[92]|new|new[96]	coref|coref	26-25[214_0]|26-25[214_0]
13-8	1962-1972	milestones	abstract[92]|event[96]	new[92]|new[96]	_	_
13-9	1973-1974	,	abstract[92]	new[92]	_	_
13-10	1975-1978	and	abstract[92]	new[92]	_	_
13-11	1979-1982	the	abstract[92]|abstract[97]	new[92]|new[97]	coref	14-8[107_97]
13-12	1983-1988	risks	abstract[92]|abstract[97]	new[92]|new[97]	_	_
13-13	1989-1995	versus	abstract[92]|abstract[97]	new[92]|new[97]	_	_
13-14	1996-2004	benefits	abstract[92]|abstract[97]|abstract[98]	new[92]|new[97]|new[98]	_	_
13-15	2005-2007	of	abstract[92]|abstract[97]|abstract[98]	new[92]|new[97]|new[98]	_	_
13-16	2008-2011	the	abstract[92]|abstract[97]|abstract[98]|abstract[100]	new[92]|new[97]|new[98]|new[100]	_	_
13-17	2012-2021	treatment	abstract[92]|abstract[97]|abstract[98]|abstract|abstract[100]	new[92]|new[97]|new[98]|giv|new[100]	_	_
13-18	2022-2029	options	abstract[92]|abstract[97]|abstract[98]|abstract[100]	new[92]|new[97]|new[98]|new[100]	_	_
13-19	2030-2036	allows	_	_	_	_
13-20	2037-2048	pharmacists	person	new	coref	16-5
13-21	2049-2051	to	_	_	_	_
13-22	2052-2058	better	_	_	_	_
13-23	2059-2065	advise	_	_	_	_
13-24	2066-2074	patients	person[102]	giv[102]	coref	16-1[0_102]
13-25	2075-2077	or	person[102]	giv[102]	_	_
13-26	2078-2085	counsel	person[102]	giv[102]	_	_
13-27	2086-2094	patients	person[102]	giv[102]	_	_
13-28	2095-2099	more	_	_	_	_
13-29	2100-2111	effectively	_	_	_	_
13-30	2112-2113	.	_	_	_	_

#Text=Nurses and prescribers are qualified to monitor toxicity risks as closely as possible .
14-1	2114-2120	Nurses	person|person[104]	new|new[104]	coref|coref|coref|coref	17-14|17-14[122_104]|17-14|17-14[122_104]
14-2	2121-2124	and	person[104]	new[104]	_	_
14-3	2125-2136	prescribers	person[104]|person	new[104]|new	ana	15-3
14-4	2137-2140	are	_	_	_	_
14-5	2141-2150	qualified	_	_	_	_
14-6	2151-2153	to	_	_	_	_
14-7	2154-2161	monitor	_	_	_	_
14-8	2162-2170	toxicity	abstract|abstract[107]	giv|giv[107]	_	_
14-9	2171-2176	risks	abstract[107]	giv[107]	_	_
14-10	2177-2179	as	_	_	_	_
14-11	2180-2187	closely	_	_	_	_
14-12	2188-2190	as	_	_	_	_
14-13	2191-2199	possible	_	_	_	_
14-14	2200-2201	.	_	_	_	_

#Text=Unfortunately , they do not necessarily do so at regular intervals .
15-1	2202-2215	Unfortunately	_	_	_	_
15-2	2216-2217	,	_	_	_	_
15-3	2218-2222	they	person	giv	coref	16-25
15-4	2223-2225	do	_	_	_	_
15-5	2226-2229	not	_	_	_	_
15-6	2230-2241	necessarily	_	_	_	_
15-7	2242-2244	do	_	_	_	_
15-8	2245-2247	so	_	_	_	_
15-9	2248-2250	at	_	_	_	_
15-10	2251-2258	regular	abstract[109]	new[109]	_	_
15-11	2259-2268	intervals	abstract[109]	new[109]	_	_
15-12	2269-2270	.	_	_	_	_

#Text=Patients can connect with pharmacists who can provide them additional information or complementary recommendations on AEs without the need for patients to rapidly contact prescribers .
16-1	2271-2279	Patients	person	giv	coref	16-21
16-2	2280-2283	can	_	_	_	_
16-3	2284-2291	connect	_	_	_	_
16-4	2292-2296	with	_	_	_	_
16-5	2297-2308	pharmacists	person	giv	ana	16-9
16-6	2309-2312	who	_	_	_	_
16-7	2313-2316	can	_	_	_	_
16-8	2317-2324	provide	_	_	_	_
16-9	2325-2329	them	person	giv	coref	17-9
16-10	2330-2340	additional	abstract[113]	new[113]	_	_
16-11	2341-2352	information	abstract[113]	new[113]	_	_
16-12	2353-2355	or	_	_	_	_
16-13	2356-2369	complementary	abstract[114]	new[114]	_	_
16-14	2370-2385	recommendations	abstract[114]	new[114]	_	_
16-15	2386-2388	on	abstract[114]	new[114]	_	_
16-16	2389-2392	AEs	abstract[114]|abstract	new[114]|giv	coref	17-2[119_0]
16-17	2393-2400	without	_	_	_	_
16-18	2401-2404	the	abstract[116]	giv[116]	_	_
16-19	2405-2409	need	abstract[116]	giv[116]	_	_
16-20	2410-2413	for	abstract[116]	giv[116]	_	_
16-21	2414-2422	patients	abstract[116]|person	giv[116]|giv	coref	20-6
16-22	2423-2425	to	_	_	_	_
16-23	2426-2433	rapidly	_	_	_	_
16-24	2434-2441	contact	_	_	_	_
16-25	2442-2453	prescribers	person	giv	coref	17-16
16-26	2454-2455	.	_	_	_	_

#Text=When more complex or serious AEs appear , pharmacists who work closely with nurses and prescribers can propose the most appropriate therapeutic strategies .
17-1	2456-2460	When	_	_	_	_
17-2	2461-2465	more	abstract[119]	giv[119]	coref	18-8[0_119]
17-3	2466-2473	complex	abstract[119]	giv[119]	_	_
17-4	2474-2476	or	abstract[119]	giv[119]	_	_
17-5	2477-2484	serious	abstract[119]	giv[119]	_	_
17-6	2485-2488	AEs	abstract[119]	giv[119]	_	_
17-7	2489-2495	appear	_	_	_	_
17-8	2496-2497	,	_	_	_	_
17-9	2498-2509	pharmacists	person	giv	_	_
17-10	2510-2513	who	_	_	_	_
17-11	2514-2518	work	_	_	_	_
17-12	2519-2526	closely	_	_	_	_
17-13	2527-2531	with	_	_	_	_
17-14	2532-2538	nurses	person|person[122]	giv|giv[122]	coref|coref	27-11|27-11
17-15	2539-2542	and	person[122]	giv[122]	_	_
17-16	2543-2554	prescribers	person[122]|person	giv[122]|giv	_	_
17-17	2555-2558	can	_	_	_	_
17-18	2559-2566	propose	_	_	_	_
17-19	2567-2570	the	abstract[124]	giv[124]	_	_
17-20	2571-2575	most	abstract[124]	giv[124]	_	_
17-21	2576-2587	appropriate	abstract[124]	giv[124]	_	_
17-22	2588-2599	therapeutic	abstract[124]	giv[124]	_	_
17-23	2600-2610	strategies	abstract[124]	giv[124]	_	_
17-24	2611-2612	.	_	_	_	_

#Text=Finally , medical oncologists able to understand AEs along with patient education and collaboration between different medical professional groups for therapeutic drug monitoring systems are needed , but further research on the aforementioned methods of relief for continued TKI use should be also performed in the future .
18-1	2613-2620	Finally	_	_	_	_
18-2	2621-2622	,	_	_	_	_
18-3	2623-2630	medical	person[125]	giv[125]	coref	27-4[221_125]
18-4	2631-2642	oncologists	person[125]	giv[125]	_	_
18-5	2643-2647	able	_	_	_	_
18-6	2648-2650	to	_	_	_	_
18-7	2651-2661	understand	_	_	_	_
18-8	2662-2665	AEs	abstract	giv	coref	21-29[168_0]
18-9	2666-2671	along	_	_	_	_
18-10	2672-2676	with	_	_	_	_
18-11	2677-2684	patient	person|abstract[128]	giv|giv[128]	coref|coref|coref|coref	19-5|26-9[206_128]|19-5|26-9[206_128]
18-12	2685-2694	education	abstract[128]	giv[128]	_	_
18-13	2695-2698	and	_	_	_	_
18-14	2699-2712	collaboration	abstract[129]	new[129]	_	_
18-15	2713-2720	between	abstract[129]	new[129]	_	_
18-16	2721-2730	different	abstract[129]|person[130]	new[129]|new[130]	_	_
18-17	2731-2738	medical	abstract[129]|person[130]	new[129]|new[130]	_	_
18-18	2739-2751	professional	abstract[129]|person[130]	new[129]|new[130]	_	_
18-19	2752-2758	groups	abstract[129]|person[130]	new[129]|new[130]	_	_
18-20	2759-2762	for	abstract[129]|person[130]	new[129]|new[130]	_	_
18-21	2763-2774	therapeutic	abstract[129]|person[130]|abstract[133]	new[129]|new[130]|new[133]	_	_
18-22	2775-2779	drug	abstract[129]|person[130]|substance|abstract[133]	new[129]|new[130]|giv|new[133]	coref	26-9
18-23	2780-2790	monitoring	abstract[129]|person[130]|event|abstract[133]	new[129]|new[130]|giv|new[133]	_	_
18-24	2791-2798	systems	abstract[129]|person[130]|abstract[133]	new[129]|new[130]|new[133]	_	_
18-25	2799-2802	are	_	_	_	_
18-26	2803-2809	needed	_	_	_	_
18-27	2810-2811	,	_	_	_	_
18-28	2812-2815	but	_	_	_	_
18-29	2816-2823	further	abstract[134]	new[134]	_	_
18-30	2824-2832	research	abstract[134]	new[134]	_	_
18-31	2833-2835	on	abstract[134]	new[134]	_	_
18-32	2836-2839	the	abstract[134]|abstract[135]	new[134]|new[135]	_	_
18-33	2840-2854	aforementioned	abstract[134]|abstract[135]	new[134]|new[135]	_	_
18-34	2855-2862	methods	abstract[134]|abstract[135]	new[134]|new[135]	_	_
18-35	2863-2865	of	abstract[134]|abstract[135]	new[134]|new[135]	_	_
18-36	2866-2872	relief	abstract[134]|abstract[135]|abstract[136]	new[134]|new[135]|new[136]	_	_
18-37	2873-2876	for	abstract[134]|abstract[135]|abstract[136]	new[134]|new[135]|new[136]	_	_
18-38	2877-2886	continued	abstract[134]|abstract[135]|abstract[136]|abstract[138]	new[134]|new[135]|new[136]|giv[138]	_	_
18-39	2887-2890	TKI	abstract[134]|abstract[135]|abstract[136]|place|abstract[138]	new[134]|new[135]|new[136]|new|giv[138]	_	_
18-40	2891-2894	use	abstract[134]|abstract[135]|abstract[136]|abstract[138]	new[134]|new[135]|new[136]|giv[138]	_	_
18-41	2895-2901	should	_	_	_	_
18-42	2902-2904	be	_	_	_	_
18-43	2905-2909	also	_	_	_	_
18-44	2910-2919	performed	_	_	_	_
18-45	2920-2922	in	_	_	_	_
18-46	2923-2926	the	time[139]	new[139]	_	_
18-47	2927-2933	future	time[139]	new[139]	_	_
18-48	2934-2935	.	_	_	_	_

#Text=The importance of proactive patient follow-up must be emphasized rather than relying on self-reporting between clinical visits .
19-1	2936-2939	The	abstract[140]	giv[140]	_	_
19-2	2940-2950	importance	abstract[140]	giv[140]	_	_
19-3	2951-2953	of	abstract[140]	giv[140]	_	_
19-4	2954-2963	proactive	abstract[140]|event[142]	giv[140]|giv[142]	coref	21-14[0_142]
19-5	2964-2971	patient	abstract[140]|person|event[142]	giv[140]|giv|giv[142]	coref	26-6
19-6	2972-2981	follow-up	abstract[140]|event[142]	giv[140]|giv[142]	_	_
19-7	2982-2986	must	_	_	_	_
19-8	2987-2989	be	_	_	_	_
19-9	2990-3000	emphasized	_	_	_	_
19-10	3001-3007	rather	_	_	_	_
19-11	3008-3012	than	_	_	_	_
19-12	3013-3020	relying	_	_	_	_
19-13	3021-3023	on	_	_	_	_
19-14	3024-3038	self-reporting	_	_	_	_
19-15	3039-3046	between	_	_	_	_
19-16	3047-3055	clinical	event[143]	new[143]	coref	20-29[156_143]
19-17	3056-3062	visits	event[143]	new[143]	_	_
19-18	3063-3064	.	_	_	_	_

#Text=A randomized trial showed that patients receiving chemotherapy for advanced cancer , web-based symptom reporting with automated clinician e-mail alerts resulted in better health-related quality of life , fewer emergency room visits , fewer hospitalizations , and superior quality-adjusted survival .
20-1	3065-3066	A	abstract[144]	new[144]	_	_
20-2	3067-3077	randomized	abstract[144]	new[144]	_	_
20-3	3078-3083	trial	abstract[144]	new[144]	_	_
20-4	3084-3090	showed	_	_	_	_
20-5	3091-3095	that	_	_	_	_
20-6	3096-3104	patients	person	giv	coref	21-31[169_0]
20-7	3105-3114	receiving	_	_	_	_
20-8	3115-3127	chemotherapy	object[146]	giv[146]	_	_
20-9	3128-3131	for	object[146]	giv[146]	_	_
20-10	3132-3140	advanced	object[146]|abstract[147]	giv[146]|new[147]	_	_
20-11	3141-3147	cancer	object[146]|abstract[147]	giv[146]|new[147]	_	_
20-12	3148-3149	,	object[146]	giv[146]	_	_
20-13	3150-3159	web-based	object[146]|abstract[148]	giv[146]|new[148]	_	_
20-14	3160-3167	symptom	object[146]|abstract[148]	giv[146]|new[148]	_	_
20-15	3168-3177	reporting	_	_	_	_
20-16	3178-3182	with	_	_	_	_
20-17	3183-3192	automated	abstract[151]	new[151]	_	_
20-18	3193-3202	clinician	person|abstract[151]	new|new[151]	coref	26-3[201_0]
20-19	3203-3209	e-mail	abstract|abstract[151]	new|new[151]	_	_
20-20	3210-3216	alerts	abstract[151]	new[151]	_	_
20-21	3217-3225	resulted	_	_	_	_
20-22	3226-3228	in	_	_	_	_
20-23	3229-3235	better	abstract[152]	new[152]	_	_
20-24	3236-3250	health-related	abstract[152]	new[152]	_	_
20-25	3251-3258	quality	abstract[152]	new[152]	_	_
20-26	3259-3261	of	abstract[152]	new[152]	_	_
20-27	3262-3266	life	abstract[152]|abstract	new[152]|giv	_	_
20-28	3267-3268	,	abstract[152]	new[152]	_	_
20-29	3269-3274	fewer	abstract[152]|event[156]	new[152]|giv[156]	coref	23-15[183_156]
20-30	3275-3284	emergency	abstract[152]|abstract|event[156]	new[152]|new|giv[156]	coref	23-12
20-31	3285-3289	room	abstract[152]|place|event[156]	new[152]|new|giv[156]	coref	23-11[181_0]
20-32	3290-3296	visits	abstract[152]|event[156]	new[152]|giv[156]	_	_
20-33	3297-3298	,	abstract[152]	new[152]	_	_
20-34	3299-3304	fewer	abstract[152]|event[157]	new[152]|new[157]	_	_
20-35	3305-3321	hospitalizations	abstract[152]|event[157]	new[152]|new[157]	_	_
20-36	3322-3323	,	abstract[152]	new[152]	_	_
20-37	3324-3327	and	abstract[152]	new[152]	_	_
20-38	3328-3336	superior	abstract[152]|event[158]	new[152]|new[158]	coref	25-7[199_158]
20-39	3337-3353	quality-adjusted	abstract[152]|event[158]	new[152]|new[158]	_	_
20-40	3354-3362	survival	abstract[152]|event[158]	new[152]|new[158]	_	_
20-41	3363-3364	.	_	_	_	_

#Text=Recently , Cheema et al. assessed the impact of an interprofessional , proactive follow-up algorithm on the incidence of dose interruptions , reductions , and the severity of AEs in patients on afatinib .
21-1	3365-3373	Recently	_	_	_	_
21-2	3374-3375	,	_	_	_	_
21-3	3376-3382	Cheema	person	new	_	_
21-4	3383-3385	et	_	_	_	_
21-5	3386-3389	al.	_	_	_	_
21-6	3390-3398	assessed	_	_	_	_
21-7	3399-3402	the	abstract[160]	new[160]	_	_
21-8	3403-3409	impact	abstract[160]	new[160]	_	_
21-9	3410-3412	of	abstract[160]	new[160]	_	_
21-10	3413-3415	an	abstract[160]|abstract[162]	new[160]|new[162]	coref	23-1[178_162]
21-11	3416-3433	interprofessional	abstract[160]|abstract[162]	new[160]|new[162]	_	_
21-12	3434-3435	,	abstract[160]|abstract[162]	new[160]|new[162]	_	_
21-13	3436-3445	proactive	abstract[160]|abstract[162]	new[160]|new[162]	_	_
21-14	3446-3455	follow-up	abstract[160]|event|abstract[162]	new[160]|giv|new[162]	coref	22-24[176_0]
21-15	3456-3465	algorithm	abstract[160]|abstract[162]	new[160]|new[162]	_	_
21-16	3466-3468	on	abstract[160]	new[160]	_	_
21-17	3469-3472	the	abstract[160]|abstract[163]	new[160]|new[163]	_	_
21-18	3473-3482	incidence	abstract[160]|abstract[163]	new[160]|new[163]	_	_
21-19	3483-3485	of	abstract[160]|abstract[163]	new[160]|new[163]	_	_
21-20	3486-3490	dose	abstract[160]|abstract[163]|quantity|abstract[165]	new[160]|new[163]|giv|new[165]	_	_
21-21	3491-3504	interruptions	abstract[160]|abstract[163]|abstract[165]	new[160]|new[163]|new[165]	_	_
21-22	3505-3506	,	abstract[160]|abstract[163]	new[160]|new[163]	_	_
21-23	3507-3517	reductions	abstract[160]|abstract[163]|event	new[160]|new[163]|new	_	_
21-24	3518-3519	,	_	_	_	_
21-25	3520-3523	and	_	_	_	_
21-26	3524-3527	the	abstract[167]	new[167]	_	_
21-27	3528-3536	severity	abstract[167]	new[167]	_	_
21-28	3537-3539	of	abstract[167]	new[167]	_	_
21-29	3540-3543	AEs	abstract[167]|abstract[168]	new[167]|giv[168]	coref	22-8[173_168]
21-30	3544-3546	in	abstract[167]|abstract[168]	new[167]|giv[168]	_	_
21-31	3547-3555	patients	abstract[167]|abstract[168]|person[169]	new[167]|giv[168]|giv[169]	coref	24-7[0_169]
21-32	3556-3558	on	abstract[167]|abstract[168]|person[169]	new[167]|giv[168]|giv[169]	_	_
21-33	3559-3567	afatinib	abstract[167]|abstract[168]|person[169]|substance	new[167]|giv[168]|giv[169]|new	_	_
21-34	3568-3569	.	_	_	_	_

#Text=The authors reported that over half of first AEs and one third of all grade 1-2 and grade ≥3 AEs were detected through proactive follow-up .
22-1	3570-3573	The	person[171]	new[171]	_	_
22-2	3574-3581	authors	person[171]	new[171]	_	_
22-3	3582-3590	reported	_	_	_	_
22-4	3591-3595	that	_	_	_	_
22-5	3596-3600	over	_	_	_	_
22-6	3601-3605	half	quantity[172]	new[172]	_	_
22-7	3606-3608	of	quantity[172]	new[172]	_	_
22-8	3609-3614	first	quantity[172]|abstract[173]	new[172]|giv[173]	coref	22-19[175_173]
22-9	3615-3618	AEs	quantity[172]|abstract[173]	new[172]|giv[173]	_	_
22-10	3619-3622	and	_	_	_	_
22-11	3623-3626	one	_	_	_	_
22-12	3627-3632	third	_	_	_	_
22-13	3633-3635	of	_	_	_	_
22-14	3636-3639	all	abstract[174]	new[174]	_	_
22-15	3640-3645	grade	abstract[174]	new[174]	_	_
22-16	3646-3649	1-2	abstract[174]	new[174]	_	_
22-17	3650-3653	and	abstract[174]	new[174]	_	_
22-18	3654-3659	grade	abstract[174]	new[174]	_	_
22-19	3660-3662	≥3	abstract[175]	giv[175]	coref	23-24[185_175]
22-20	3663-3666	AEs	abstract[175]	giv[175]	_	_
22-21	3667-3671	were	_	_	_	_
22-22	3672-3680	detected	_	_	_	_
22-23	3681-3688	through	_	_	_	_
22-24	3689-3698	proactive	event[176]	giv[176]	coref	24-19[193_176]
22-25	3699-3708	follow-up	event[176]	giv[176]	_	_
22-26	3709-3710	.	_	_	_	_

#Text=This multi-disciplinary AE algorithm resulted in a low rate of costly emergency room or urgent clinic visits and a reduced incidence of severe drug-related AEs and discontinuation therapy .
23-1	3711-3715	This	abstract[178]	giv[178]	_	_
23-2	3716-3734	multi-disciplinary	abstract[178]	giv[178]	_	_
23-3	3735-3737	AE	abstract|abstract[178]	new|giv[178]	_	_
23-4	3738-3747	algorithm	abstract[178]	giv[178]	_	_
23-5	3748-3756	resulted	_	_	_	_
23-6	3757-3759	in	_	_	_	_
23-7	3760-3761	a	quantity[179]	new[179]	_	_
23-8	3762-3765	low	quantity[179]	new[179]	_	_
23-9	3766-3770	rate	quantity[179]	new[179]	_	_
23-10	3771-3773	of	quantity[179]	new[179]	_	_
23-11	3774-3780	costly	quantity[179]|place[181]	new[179]|giv[181]	_	_
23-12	3781-3790	emergency	quantity[179]|abstract|place[181]	new[179]|giv|giv[181]	_	_
23-13	3791-3795	room	quantity[179]|place[181]	new[179]|giv[181]	_	_
23-14	3796-3798	or	quantity[179]	new[179]	_	_
23-15	3799-3805	urgent	quantity[179]|event[183]	new[179]|giv[183]	_	_
23-16	3806-3812	clinic	quantity[179]|place|event[183]	new[179]|new|giv[183]	_	_
23-17	3813-3819	visits	quantity[179]|event[183]	new[179]|giv[183]	_	_
23-18	3820-3823	and	quantity[179]	new[179]	_	_
23-19	3824-3825	a	quantity[179]|abstract[184]	new[179]|new[184]	_	_
23-20	3826-3833	reduced	quantity[179]|abstract[184]	new[179]|new[184]	_	_
23-21	3834-3843	incidence	quantity[179]|abstract[184]	new[179]|new[184]	_	_
23-22	3844-3846	of	quantity[179]|abstract[184]	new[179]|new[184]	_	_
23-23	3847-3853	severe	quantity[179]|abstract[184]|abstract[187]	new[179]|new[184]|new[187]	_	_
23-24	3854-3866	drug-related	quantity[179]|abstract[184]|abstract[185]|abstract[187]	new[179]|new[184]|giv[185]|new[187]	_	_
23-25	3867-3870	AEs	quantity[179]|abstract[184]|abstract[185]|abstract[187]	new[179]|new[184]|giv[185]|new[187]	_	_
23-26	3871-3874	and	quantity[179]|abstract[184]|abstract[187]	new[179]|new[184]|new[187]	_	_
23-27	3875-3890	discontinuation	quantity[179]|abstract[184]|event|abstract[187]	new[179]|new[184]|giv|new[187]	_	_
23-28	3891-3898	therapy	quantity[179]|abstract[184]|abstract[187]	new[179]|new[184]|new[187]	_	_
23-29	3899-3900	.	_	_	_	_

#Text=In conclusion , when closely monitoring patients , the ability of clinicians to make rapid therapeutic decisions in the event of medical complications is critical in the diagnosis and management of TKI-related side effects .
24-1	3901-3903	In	_	_	_	_
24-2	3904-3914	conclusion	abstract	new	_	_
24-3	3915-3916	,	_	_	_	_
24-4	3917-3921	when	_	_	_	_
24-5	3922-3929	closely	_	_	_	_
24-6	3930-3940	monitoring	_	_	_	_
24-7	3941-3949	patients	person	giv	coref	27-23[227_0]
24-8	3950-3951	,	_	_	_	_
24-9	3952-3955	the	abstract[190]	new[190]	_	_
24-10	3956-3963	ability	abstract[190]	new[190]	_	_
24-11	3964-3966	of	abstract[190]	new[190]	_	_
24-12	3967-3977	clinicians	abstract[190]|person	new[190]|new	_	_
24-13	3978-3980	to	_	_	_	_
24-14	3981-3985	make	_	_	_	_
24-15	3986-3991	rapid	abstract[192]	new[192]	_	_
24-16	3992-4003	therapeutic	abstract[192]	new[192]	_	_
24-17	4004-4013	decisions	abstract[192]	new[192]	_	_
24-18	4014-4016	in	_	_	_	_
24-19	4017-4020	the	event[193]	giv[193]	_	_
24-20	4021-4026	event	event[193]	giv[193]	_	_
24-21	4027-4029	of	event[193]	giv[193]	_	_
24-22	4030-4037	medical	event[193]|abstract[194]	giv[193]|new[194]	coref	25-10[200_194]
24-23	4038-4051	complications	event[193]|abstract[194]	giv[193]|new[194]	_	_
24-24	4052-4054	is	_	_	_	_
24-25	4055-4063	critical	_	_	_	_
24-26	4064-4066	in	_	_	_	_
24-27	4067-4070	the	abstract[195]	new[195]	ana	25-1[0_195]
24-28	4071-4080	diagnosis	abstract[195]	new[195]	_	_
24-29	4081-4084	and	_	_	_	_
24-30	4085-4095	management	organization[196]	new[196]	_	_
24-31	4096-4098	of	organization[196]	new[196]	_	_
24-32	4099-4110	TKI-related	organization[196]|abstract[197]	new[196]|giv[197]	coref	26-18[211_197]
24-33	4111-4115	side	organization[196]|abstract[197]	new[196]|giv[197]	_	_
24-34	4116-4123	effects	organization[196]|abstract[197]	new[196]|giv[197]	_	_
24-35	4124-4125	.	_	_	_	_

#Text=This is even more decisive in the event of serious or even life-threatening complications .
25-1	4126-4130	This	abstract	giv	_	_
25-2	4131-4133	is	_	_	_	_
25-3	4134-4138	even	_	_	_	_
25-4	4139-4143	more	_	_	_	_
25-5	4144-4152	decisive	_	_	_	_
25-6	4153-4155	in	_	_	_	_
25-7	4156-4159	the	event[199]	giv[199]	_	_
25-8	4160-4165	event	event[199]	giv[199]	_	_
25-9	4166-4168	of	event[199]	giv[199]	_	_
25-10	4169-4176	serious	event[199]|abstract[200]	giv[199]|giv[200]	_	_
25-11	4177-4179	or	event[199]|abstract[200]	giv[199]|giv[200]	_	_
25-12	4180-4184	even	event[199]|abstract[200]	giv[199]|giv[200]	_	_
25-13	4185-4201	life-threatening	event[199]|abstract[200]	giv[199]|giv[200]	_	_
25-14	4202-4215	complications	event[199]|abstract[200]	giv[199]|giv[200]	_	_
25-15	4216-4217	.	_	_	_	_

#Text=However , good clinician – patient communication , drug patient education , early detection and management of drug side effects , and monitoring of disease response with plasma concentration quantification can also improve patient outcomes .
26-1	4218-4225	However	_	_	_	_
26-2	4226-4227	,	_	_	_	_
26-3	4228-4232	good	person[201]	giv[201]	_	_
26-4	4233-4242	clinician	person[201]	giv[201]	_	_
26-5	4243-4244	–	_	_	_	_
26-6	4245-4252	patient	person|abstract[203]	giv|new[203]	coref|coref	26-10|26-10
26-7	4253-4266	communication	abstract[203]	new[203]	_	_
26-8	4267-4268	,	_	_	_	_
26-9	4269-4273	drug	substance|abstract[206]	giv|giv[206]	coref|coref	26-18|26-18
26-10	4274-4281	patient	person|abstract[206]	giv|giv[206]	coref	26-34
26-11	4282-4291	education	abstract[206]	giv[206]	_	_
26-12	4292-4293	,	_	_	_	_
26-13	4294-4299	early	abstract[207]	new[207]	_	_
26-14	4300-4309	detection	abstract[207]	new[207]	_	_
26-15	4310-4313	and	_	_	_	_
26-16	4314-4324	management	organization[208]	new[208]	_	_
26-17	4325-4327	of	organization[208]	new[208]	_	_
26-18	4328-4332	drug	organization[208]|substance|abstract[211]	new[208]|giv|giv[211]	_	_
26-19	4333-4337	side	organization[208]|abstract|abstract[211]	new[208]|new|giv[211]	_	_
26-20	4338-4345	effects	organization[208]|abstract[211]	new[208]|giv[211]	_	_
26-21	4346-4347	,	_	_	_	_
26-22	4348-4351	and	_	_	_	_
26-23	4352-4362	monitoring	event[212]	new[212]	_	_
26-24	4363-4365	of	event[212]	new[212]	_	_
26-25	4366-4373	disease	event[212]|abstract|abstract[214]	new[212]|giv|giv[214]	_	_
26-26	4374-4382	response	event[212]|abstract[214]	new[212]|giv[214]	_	_
26-27	4383-4387	with	event[212]|abstract[214]	new[212]|giv[214]	_	_
26-28	4388-4394	plasma	event[212]|abstract[214]|abstract|abstract[217]	new[212]|giv[214]|new|new[217]	_	_
26-29	4395-4408	concentration	event[212]|abstract[214]|abstract|abstract[217]	new[212]|giv[214]|new|new[217]	_	_
26-30	4409-4423	quantification	event[212]|abstract[214]|abstract[217]	new[212]|giv[214]|new[217]	_	_
26-31	4424-4427	can	_	_	_	_
26-32	4428-4432	also	_	_	_	_
26-33	4433-4440	improve	_	_	_	_
26-34	4441-4448	patient	person|abstract[219]	giv|new[219]	_	_
26-35	4449-4457	outcomes	abstract[219]	new[219]	_	_
26-36	4458-4459	.	_	_	_	_

#Text=Close cooperation between oncologists , internists , pharmaceutics , and nurses should become the gold standard in the comprehensive clinical care of advanced NSCLC patients receiving TKIs .
27-1	4460-4465	Close	abstract[220]	new[220]	_	_
27-2	4466-4477	cooperation	abstract[220]	new[220]	_	_
27-3	4478-4485	between	abstract[220]	new[220]	_	_
27-4	4486-4497	oncologists	abstract[220]|person[221]	new[220]|giv[221]	_	_
27-5	4498-4499	,	abstract[220]|person[221]	new[220]|giv[221]	_	_
27-6	4500-4510	internists	abstract[220]|person[221]|person	new[220]|giv[221]|new	_	_
27-7	4511-4512	,	abstract[220]|person[221]	new[220]|giv[221]	_	_
27-8	4513-4526	pharmaceutics	abstract[220]|person[221]|person	new[220]|giv[221]|new	_	_
27-9	4527-4528	,	abstract[220]|person[221]	new[220]|giv[221]	_	_
27-10	4529-4532	and	abstract[220]|person[221]	new[220]|giv[221]	_	_
27-11	4533-4539	nurses	abstract[220]|person[221]|person	new[220]|giv[221]|giv	_	_
27-12	4540-4546	should	_	_	_	_
27-13	4547-4553	become	_	_	_	_
27-14	4554-4557	the	_	_	_	_
27-15	4558-4562	gold	_	_	_	_
27-16	4563-4571	standard	_	_	_	_
27-17	4572-4574	in	_	_	_	_
27-18	4575-4578	the	abstract[225]	giv[225]	_	_
27-19	4579-4592	comprehensive	abstract[225]	giv[225]	_	_
27-20	4593-4601	clinical	abstract[225]	giv[225]	_	_
27-21	4602-4606	care	abstract[225]	giv[225]	_	_
27-22	4607-4609	of	abstract[225]	giv[225]	_	_
27-23	4610-4618	advanced	abstract[225]|person[227]	giv[225]|giv[227]	_	_
27-24	4619-4624	NSCLC	abstract[225]|abstract|person[227]	giv[225]|giv|giv[227]	_	_
27-25	4625-4633	patients	abstract[225]|person[227]	giv[225]|giv[227]	_	_
27-26	4634-4643	receiving	_	_	_	_
27-27	4644-4648	TKIs	event	new	_	_
27-28	4649-4650	.	_	_	_	_
